(Q41019483)

25 September 2017

title

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation (English)

1 reference

25 September 2017

0 references

Aviram M

1

1 reference

25 September 2017

Rosenblat M

series ordinal

2

1 reference

25 September 2017

Bisgaier CL

series ordinal

3

1 reference

25 September 2017

Newton RS

series ordinal

4

1 reference

25 September 2017

publication date

1 June 1998

1 reference

25 September 2017

1 reference

25 September 2017

volume

138

1 reference

25 September 2017

issue

2

1 reference

25 September 2017

page(s)

271-280

1 reference

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized very-low-density lipoprotein (VLDL), but increase cellular degradation of native VLDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Role of vitamin E in preventing the oxidation of low-density lipoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Physiological disposition of HMG-CoA-reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Fibric acids: effects on lipids and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Biosynthesis, characterisation and direct high-performance liquid chromatographic analysis of gemfibrozil 1-O-beta-acylglucuronide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Antioxidant defenses and lipid peroxidation in human blood plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Microsomal lipid peroxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Continuous monitoring of in vitro oxidation of human low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Antioxidant Determinations by the Use of a Stable Free Radical

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Oxidized low density lipoproteins in atherogenesis: role of dietary modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Structural and functional diversity of paraoxonases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900032-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(98)00032-X

1 reference

release_4kr6d3wv5bbvjphvc2qixgjkfq

25 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4kr6d3wv5bbvjphvc2qixgjkfq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference